Top

Published in:

01-08-2007 | Correspondence

Is there increasing evidence that the risks of rhAPC may outweigh its benefits?

Authors: Maria Plataki, Katerina Vaporidi, Dimitris Georgopoulos

Published in: Intensive Care Medicine | Issue 8/2007

Excerpt

Sir, It is true that the use of rhAPC in critically ill patients with sepsis has raised a lot of controversy and we read with great interest the concerns of Eichacker and Natanson in their editorial in “Intensive Care Medicine” [1]. We believe, however, that their comparisons and conclusions, in view of the recently published surveys by Kanji et al. [2] and Bertolini et al. [3], do not take into consideration significant limitations and differences in the studies on rhAPC published to date. …

Eichacker PQ, Natanson C (2007) Increasing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Med 33:396–399PubMedCrossRef

Kanji S, Perreault MM, Chant C, Williamson D, Burry L (2007) Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. Intensive Care Med 33:517–523PubMedCrossRef

Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D (2007) Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Med 33:426–434PubMedCrossRef

Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Wesley Ely E, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709PubMedCrossRef

Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33:2266–2277PubMedCrossRef

Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B (2007) Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomized controlled trial. Lancet 369:836–843PubMedCrossRef

Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353:1332–1341PubMedCrossRef

Tanzi M (2004) Use of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis: medical use evaluation by Novation, the supply company of VHA and UHC. Novation

Title: Is there increasing evidence that the risks of rhAPC may outweigh its benefits?
Authors: Maria Plataki
Katerina Vaporidi
Dimitris Georgopoulos
Publication date: 01-08-2007
Publisher: Springer-Verlag
Published in: Intensive Care Medicine / Issue 8/2007
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-007-0707-y

At a glance: The STEP trials

Springer Medicine

Is there increasing evidence that the risks of rhAPC may outweigh its benefits?

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2007

A method for monitoring and improving patient: ventilator interaction

Withdrawal symptoms in children after long-term administration of sedatives and/or analgesics: a literature review. “Assessment remains troublesome”

High-mobility group box 1 protein plasma concentrations during septic shock

Reply to Moser and Röggla

Management of ventilator-associated pneumonia in a multidisciplinary intensive care unit: does trauma make a difference?

Variability in outcome and resource use in intensive care units